Olive Ridley turtles choose mates of similar size, reveals new study
A study published in the journal
Ecosphere
by scientists from the Kolkata-based Zoological Survey of India (ZSI) and the University of Michigan revealed that olive ridley sea turtles—a vulnerable species listed on the IUCN Red List—prefer mating with partners of similar size.
Some species of animals where males maintain a territory, are bigger in size as compared to females. In contrast to these animals, Olive Ridley females are bigger in size to accommodate the eggs inside their body. The Olive Ridley Sea turtles do not mate with random sized mates. They are mating with a preferred sized mate, the research finds.
The research, conducted over two years at Odisha's Rushikulya rookery, one of the world's largest mass nesting sites for the species, involved capturing, tagging, and measuring 134 mating pairs. The study found a strong positive correlation between the sizes of male and female turtles, indicating size-assortative mating behaviour.
'This preference may be shaped by biological advantages,' said Dhriti Banerjee, ZSI director. 'Larger females tend to lay more eggs, and larger males may have a competitive edge during mating.' The team also recorded signs of intense mating competition, including bite marks on females and instances of multiple males attempting to mate with a single female.
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Your Finger Shape Says a Lot About Your Personality, Read Now
Tips and Tricks
Undo
Olive Ridley turtles are important because they are crucial in maintaining healthy marine ecosystems. They are a vital part of the food chain, helping regulate populations of other marine organisms, like jellyfish. Additionally, their nesting habits on beaches enrich coastal ecosystems and contribute to biodiversity.
Their nesting on beaches enriches the environment by contributing to the nutrient cycle and providing habitat for other species.
The research was led by Basudev Tripathy and Anil Mohapatra of ZSI, along with Anshuman Swain from the University of Michigan and Ashis Kumar Das and Sandeep Kumar Mohapatra from ZSI's Gopalpur-on-Sea centre.
The study not only sheds light on a previously little-understood aspect of olive ridley behaviour but also underscores the importance of targeted conservation. 'There are many unknown aspects of the biology of olive ridleys. Monitoring and reducing high sea mortality is essential for their long-term survival,' added Banerjee.
The Rushikulya rookery, discovered in 1994, has shown a steady rise in nesting females thanks to sustained conservation efforts. Tripathy, who has monitored the beach for nearly three decades, noted the positive trend: 'The number of nesting females has been growing due to our persistent protection and habitat monitoring work.'
The need to protect Olive Ridley turtles and their nesting grounds underscores the importance of their role in maintaining healthy ocean ecosystems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
Time of India
3 hours ago
- Time of India
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda HYDERABAD: Dr Reddy's Laboratories has entered into a collaboration and license agreement with Iceland-based biotech player Alvotech for the co-development, manufacturing and commercialiation of a biosimilar of Merck Sharp & Dohme's blockbuster drug Keytruda (pembrolizumab). Keytruda, which is used for the treatment of various types of cancer, clocked sales of over US$29.5 billion in 2024. The collaboration will combine Dr Reddy's and Alvotech's capabilities in biosimilars to speed up the development process and extend the global reach of the biosimilar candidate. As per the agreement, the two companies will share the costs and responsibilities for jointly developing and manufacturing the biosimilar candidate and subject to certain exceptions, each company will have the right to commercialise the product globally, Dr Reddy's said on Thursday. 'The agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide,' said Róbert Wessman, chairman & CEO, Alvotech. Dr Reddy's CEO, Erez Israeli, said the pact demonstrates the company's ability to develop and manufacture high-quality and affordable treatment options for patients worldwide. 'Oncology has been a top focus therapy area for us, and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Israeli added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Mint
4 hours ago
- Mint
Explainer: What is agro-terrorism and fusarium graminearum threat fueling the US-China tensions?
The recent arrest of a Chinese researcher and charges against another for smuggling a dangerous crop-killing fungus into the United States have brought renewed attention to the threat of agro-terrorism. At the heart of the case is Fusarium graminearum, a potent plant pathogen capable of devastating cereal crops and disrupting national food supplies. US officials allege the two researchers, one of whom worked at a University of Michigan lab, intended to conduct unauthorized research on the fungus—raising fears of deliberate attempts to compromise American agriculture. The incident, unfolding amid heightened US-China tensions and trade disputes, highlights how scientific collaboration can be exploited to target a country's most vulnerable infrastructure: its food system. What is agro-terrorism? Agro-terrorism is the intentional use of biological agents—such as plant pathogens, pests, or contaminants—to attack a country's agricultural infrastructure. It targets food production systems with the aim of causing economic devastation, food insecurity, and public panic. Agro-terrorism is attractive to hostile actors because it is low-cost, difficult to detect, and capable of triggering far-reaching economic and social damage. Why agriculture is a soft target Agriculture-based sectors are especially vulnerable. Unlike military or financial systems, farms, food processing plants, and supply chains are less protected and widely dispersed. Biological attacks on crops or livestock can go undetected for weeks and are difficult to trace back to the perpetrators. This makes agro-terrorism a potent weapon for countries or groups seeking to destabilize a rival nation. Fusarium graminearum: A potent agro-terrorism threat At the center of the current controversy is Fusarium graminearum, a fungus that causes Fusarium head blight—a disease that ravages cereal crops such as wheat, barley, maize, and rice. The fungus not only decimates yields but also produces a toxin called vomitoxin (deoxynivalenol), making the grain unsafe for human and animal consumption. According to the US Department of Agriculture, this disease causes over $1 billion in crop losses annually in the United States alone. Vomitoxin can cause vomiting, diarrhea, abdominal pain, and fever in livestock and people, further amplifying its public health impact. The case: Chinese researchers charged Two Chinese nationals, Yunqing Jian (33) and Zunyong Liu (34), have been charged by US federal prosecutors with smuggling Fusarium graminearum into the United States—without proper permits and under false pretenses. Jian, who works at the University of Michigan, is currently in US custody. Liu, her boyfriend and a researcher in China, is believed to be in China and remains at large. According to the FBI, Liu carried baggies of the fungus into the US via the Detroit airport and initially lied about them. He later admitted he intended to use them for research in a Michigan lab. Jian allegedly received Chinese government funding for similar research and has expressed loyalty to the Chinese Communist Party (CCP). US Attorney Jerome Gorgon Jr. described the smuggling as a 'national security' concern, emphasizing the CCP ties and the threat to America's food supply. Why this matters Although Fusarium graminearum already exists in the US, the unauthorised import of foreign strains is dangerous. Variants may be more virulent, pesticide-resistant, or adapted to new climates—making them harder to contain. Bringing them in without the proper biosecurity controls risks new outbreaks or genetic mutations that existing defenses can't manage. FBI Director Kash Patel warned that this could have "grave consequences... putting American lives and our economy at serious risk." He emphasised that this case illustrates how state-backed actors may attempt to infiltrate US institutions and compromise critical sectors like food security. Wider context: US-China tensions This incident comes amid deteriorating relations between Washington and Beijing. US-China trade talks stall after Geneva tariff truce Trade negotiations between the United States and China have stalled, just weeks after both sides agreed in Geneva to a 90-day cooling-off period by reducing tariffs. The agreement had seen China cut tariffs on American goods from 125% to 10%, while the U.S. proposed lowering its tariffs on Chinese imports from 145% to 30%. However, progress has faltered amid renewed tensions. U.S. President Donald Trump reignited the dispute on May 30, accusing China of 'totally violating' the Geneva deal, though he did not provide specifics. 'So much for being Mr. NICE GUY!' he wrote on social media. In response, China's Commerce Ministry denied any violations and accused Washington of making 'bogus charges' and taking 'unreasonable' actions, including export controls on AI chips and revoking Chinese student visas. The Trump administration has also recently announced a crackdown on Chinese student visas, citing national security threats. US Secretary of State Marco Rubio pledged to 'aggressively revoke' visas for Chinese students in sensitive research fields—moves Beijing has denounced as 'discriminatory.'
